Tarsus: XDEMVY sales jump, but acquired R&D pushes Q3 loss to $668.3 million
Q3 XDEMVY sales rose about 64% year over year, while $632.2 million in acquired IPR&D expense drove a $668.3 million net loss, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, XDEMVY sales in the third quarter grew roughly 64% from a year earlier. Meanwhile, acquisitions added new pipeline assets and brought $632.2 million of acquired IPR&D expense.
Those charges drove a net loss of $668.3 million. Key clinical readouts are expected between the first half of 2027 and 2029.
why it matters
For investors, the bigger question is less the loss tied to the deals and more how quickly XDEMVY's sales growth and upcoming clinical data will show up in the company's financial results.
market impact
TARS: XDEMVY sales growth set against a deal-driven loss, focus shifts to revenue momentum
tags
instruments
sources
- TARS: XDEMVY sales surged, while acquisition-related IPR&D drove a $668.3 million Q3 loss — TradingView, 3 November 2026 at 21:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗